电邮这篇文章 Contrast Agents Based on Iron Oxide Nanoparticles for Clinical Magnetic Resonance Imaging
- 作者: Abakumov M.1,2, Ternovoi S.3,4, Mazhuga A.2,5,6, Chekhonin V.1, Demikhov E.7, Pistrak A.7, Konstantinov M.7, Dmitriev D.7, Myshkinis B.8
-
隶属关系:
- N. I. Pirogov Russian Research Medical University, Ministry of Health of the Russian Federation
- Biomedical Nanomaterials Laboratory, National University of Science and Technology MISIS
- National Medical Research Center for Cardiology, Ministry of Health of the Russian Federation
- I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation
- Faculty of Chemistry, M. V. Lomonosov Moscow State University
- D. I. Mendeleev Russian Chemical Technological University
- P. N. Lebedev Physical Institute, Russian Academy of Sciences
- Gelpik Company
- 期: 卷 167, 编号 2 (2019)
- 页面: 272-274
- 栏目: Biotechnologies
- URL: https://journals.rcsi.science/0007-4888/article/view/241637
- DOI: https://doi.org/10.1007/s10517-019-04507-y
- ID: 241637
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
Magnetic resonance imaging (MRI) is one of the most perspective methods of noninvasive visualization in medicine, and use of contrast agents significantly its potentialities extends. Iron oxide nanoparticles are promising contrast agents, but in fact all the data on their efficiency were obtained in high-field tomographs for experimental animals. We studied the possibility of using magnetic nanoparticles for MRI visualization of rat brain glioblastoma at the most common clinical field 1.5 T The data indicate the efficiency of iron oxide magnetic nanoparticles as contrast agents for 1.5 T MR tomographs.
作者简介
M. Abakumov
N. I. Pirogov Russian Research Medical University, Ministry of Health of the Russian Federation; Biomedical Nanomaterials Laboratory, National University of Science and Technology MISIS
编辑信件的主要联系方式.
Email: abakumov1988@gmail.com
俄罗斯联邦, Moscow; Moscow
S. Ternovoi
National Medical Research Center for Cardiology, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation
Email: abakumov1988@gmail.com
俄罗斯联邦, Moscow; Moscow
A. Mazhuga
Biomedical Nanomaterials Laboratory, National University of Science and Technology MISIS; Faculty of Chemistry, M. V. Lomonosov Moscow State University; D. I. Mendeleev Russian Chemical Technological University
Email: abakumov1988@gmail.com
俄罗斯联邦, Moscow; Moscow; Moscow
V. Chekhonin
N. I. Pirogov Russian Research Medical University, Ministry of Health of the Russian Federation
Email: abakumov1988@gmail.com
俄罗斯联邦, Moscow
E. Demikhov
P. N. Lebedev Physical Institute, Russian Academy of Sciences
Email: abakumov1988@gmail.com
俄罗斯联邦, Moskva
A. Pistrak
P. N. Lebedev Physical Institute, Russian Academy of Sciences
Email: abakumov1988@gmail.com
俄罗斯联邦, Moskva
M. Konstantinov
P. N. Lebedev Physical Institute, Russian Academy of Sciences
Email: abakumov1988@gmail.com
俄罗斯联邦, Moskva
D. Dmitriev
P. N. Lebedev Physical Institute, Russian Academy of Sciences
Email: abakumov1988@gmail.com
俄罗斯联邦, Moskva
B. Myshkinis
Gelpik Company
Email: abakumov1988@gmail.com
俄罗斯联邦, Moscow
